Get started
Author

Karl‐Gustav Jostell

Observed name: Karl-Gustav Jostell
Observed institution: AstraZeneca (Sweden)
OpenAlex ID: A5111972530
AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects
2012 · Aurelija Jucaite, Akihiro Takano, et al. · The International Journal of Neuropsychopharmacology · 55
Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke
2002 · Stig Strid, Olof Borgå, et al. · European Journal of Clinical Pharmacology · 27
Selective dopamine D2 antagonist and prolactin response in acute schizophrenia — Results from remoxipride studies
1990 · A.George Awad, Yvon D Lapierre, et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 12
Population pharmacokinetics and safety of AZD1446, a neuronal nicotinic receptor agonist, administered in healthy volunteers
2013 · Emma Boström, Kristina Claeson Bohnstedt, et al. · Clinical Pharmacology in Drug Development · 2
Pharmacokinetics of Chlormethiazole in man and influence of altered physiological conditions
1987 · Karl‐Gustav Jostell · Acta pharmaceutica Suecica · 2
Works count: 5
Citation count: 98
H-index: 3
I10-index: 3
Year
Topic
Type